Table 1 Patient characteristics at baseline and follow-up
From: IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment
Baseline | Follow-up | p-value | |
|---|---|---|---|
Creatinine, μmol/l, median | 82 (52–284) | 77 (48–306) | ns |
Proteinuria, g/d, median | 1.45 (0–8.4) | 0.5 (0–3.6) | <0.001 |
C3, g/l, median | 0.5 (0.12-1.13) | 0.74 (0.36-1.41) | <0.001 |
C4, g/l, median | 0.11 (0.02-0.51) | 0.13 (0.02-0.45) | 0.002 |
Anti-DNA-ab positivity # , % | 84 | 57 | |
Nephritis class, WHO (n) | |||
I-II | - | 19 | |
III | 15 | 9 | |
III/V | 4 | 1 | |
IV | 24 | 8 | |
V | 8 | 14 | |
Vasculits | 1 | 1 | |
Activity index, median | 5 (0–13) | 2 (0–12) | <0.001 |
Chronicity index, median | 1 (0–6) | 1 (0–8) | <0.001 |
Treatment (n) | |||
Cyclophosphamide | 40 | ||
Mycophenolate mofetil | 9 | ||
Rituximab | 2 | ||
Azathioprin | 1 | ||
Prednisolone dose, median | 40 (2.5-80) | 10 (2.5-30) | |
BILAG † , renal | |||
A | 49 | 8 | |
B | 3 | 20 | |
C | 12 | ||
D | 12 |